Calculated Whole Blood Viscosity and Albumin/Fibrinogen Ratio in Patients with a New Diagnosis of Multiple Myeloma: Relationships with Some Prognostic Predictors
暂无分享,去创建一个
[1] G. Caimi,et al. Erythrocyte deformability profile evaluated by laser diffractometry in patients with multiple myeloma: Re-examination of our cases. , 2022, Microvascular research.
[2] Min Zhou,et al. Application of clinical nomograms to predicting overall survival and event-free survival in multiple myeloma patients: Visualization tools for prognostic stratification , 2022, Frontiers in Public Health.
[3] J. Suh,et al. Red Blood Cell Deformability and Distribution Width in Patients with Hematologic Neoplasms. , 2022, Clinical laboratory.
[4] Jiayue Liu,et al. Is RDW a clinically relevant prognostic factor for newly diagnosed multiple myeloma? A systematic review and meta-analysis , 2022, BMC cancer.
[5] Tracy Holloway King,et al. Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR) , 2022, British journal of haematology.
[6] G. Castellani,et al. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] M. D'Agostino,et al. Risk Stratification Before and During Treatment in Newly Diagnosed Multiple Myeloma: From Clinical Trials to the Real-World Setting , 2022, Frontiers in Oncology.
[8] A. Kraśniak,et al. The Key Role of Hepcidin-25 in Anemia in Multiple Myeloma Patients with Renal Impairment , 2022, Medicina.
[9] A. Titov,et al. Knowns and Unknowns about CAR-T Cell Dysfunction , 2022, Cancers.
[10] Yu Hu,et al. Prognostic nomogram incorporating cytokines for overall survival in patients with newly diagnosed multiple myeloma. , 2021, International immunopharmacology.
[11] G. Caimi,et al. Comparison between whole blood viscosity measured and calculated in subjects with monoclonal gammopathy of undetermined significance and in patients with multiple myeloma: Re-evaluation of our survey. , 2021, Clinical hemorheology and microcirculation.
[12] G. Caimi,et al. Reflections on the unexpected laboratory finding of hemorheological alterations observed in some haematological disorders. , 2021, Microvascular research.
[13] J. Roliński,et al. Immunological Prognostic Factors in Multiple Myeloma , 2021, International journal of molecular sciences.
[14] D. Dingli,et al. Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. , 2020, Clinical lymphoma, myeloma & leukemia.
[15] H. Dürr,et al. Tumor load in patients with multiple myeloma: β₂‐microglobulin levels versus low‐dose whole‐body CT , 2019, European journal of haematology.
[16] N. Mishra,et al. Blood Viscosity, Glycemic Markers and Blood Pressure: A Study in Middle-Aged Normotensive and Hypertensive Type 2 Diabetics , 2018, Indian Journal of Clinical Biochemistry.
[17] Peipei Xu,et al. Pre-treatment red blood cell distribution width provides prognostic information in multiple myeloma. , 2018, Clinica chimica acta; international journal of clinical chemistry.
[18] Yu Hu,et al. Prognostic role of RDW in hematological malignancies: a systematic review and meta-analysis , 2018, Cancer Cell International.
[19] G. Caimi,et al. Erythrocyte deformability and hemorheological profile in multiple myeloma. , 2017, Clinical hemorheology and microcirculation.
[20] G. Caimi,et al. Red blood cell deformability in multiple myeloma1. , 2018, Clinical hemorheology and microcirculation.
[21] P. Julia,et al. Serum Hepcidin Levels in Multiple Myeloma. , 2017, Clinical laboratory.
[22] Jie Jin,et al. Analysis of clinical characteristics and prognostic factors of multiple myeloma: a retrospective single-center study of 787 cases , 2017, Hematology.
[23] M. Aljurf,et al. The Evolution of Prognostic Factors in Multiple Myeloma , 2017, Advances in hematology.
[24] S. Hasić,et al. Dilemma: Correlation Between Serum Level of Hepcidin and IL-6 in Anemic Myeloma Patients , 2016, Medical archives.
[25] R. Advani,et al. The World Health Organization Classification of Lymphoid Neoplasms , 2013 .
[26] H. Goldschmidt,et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] A. Vangsted,et al. Causes of early death in multiple myeloma patients who are ineligible for high‐dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma Database , 2015, American journal of hematology.
[28] Hong Liu,et al. Hepcidin and GDF15 in anemia of multiple myeloma , 2014, International Journal of Hematology.
[29] H. Goldschmidt,et al. IMWG consensus on risk stratification in multiple myeloma , 2014, Leukemia.
[30] S. Vincent Rajkumar,et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients , 2013, Leukemia.
[31] Neelima Singh,et al. Blood Viscosity, Lipid Profile, and Lipid Peroxidation in Type-1 Diabetic Patients with Good and Poor Glycemic Control , 2013, North American journal of medical sciences.
[32] K. Patel,et al. Association of the red cell distribution width with red blood cell deformability. , 2013, Advances in experimental medicine and biology.
[33] H. Kwaan. Hyperviscosity in plasma cell dyscrasias. , 2013, Clinical hemorheology and microcirculation.
[34] S. Ševčíková,et al. Prognostic significance of morphological assessment of plasma cells in multiple myeloma. , 2011, Neoplasma.
[35] D. Rossi,et al. Beta‐2‐microglobulin is an independent predictor of progression in asymptomatic multiple myeloma , 2010, Cancer.
[36] Sang-We Kim,et al. Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma , 2010, Annals of Hematology.
[37] B. Barlogie,et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review , 2009, Leukemia.
[38] D. Meyerstein,et al. A novel technique for quantification of erythrocyte aggregation abnormalities in pathophysiological situations. , 2007, Clinical hemorheology and microcirculation.
[39] O. Baskurt,et al. Hemodynamic effects of red blood cell aggregation. , 2007, Indian journal of experimental biology.
[40] J. Crowley,et al. International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] V. Lauta,et al. A review of the cytokine network in multiple myeloma , 2003, Cancer.
[42] Terry L. Smith,et al. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. , 1991, Annals of internal medicine.
[43] M. C. Magalhães,et al. Hypoalbuminemia in patients with multiple myeloma. , 1990, Archives of internal medicine.
[44] S Chien,et al. Relation of blood viscosity to demographic and physiologic variables and to cardiovascular risk factors in apparently normal adults. , 1990, Circulation.
[45] M. Jourdan,et al. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. , 1989, The Journal of clinical investigation.
[46] Dr H. Oakervee. Myeloma , 2002, Lyon medical.
[47] E. Merrill,et al. Yield stress of normal human blood as a function of endogenous fibrinogen. , 1969, Journal of applied physiology.
[48] L. Langstroth. BLOOD VISCOSITY , 1919, The Journal of experimental medicine.